65,437 trials
Infections, Papillomavirus · Papillomavirus Vaccines
Primary: Number of Subjects Seroprotected Against Hepatitis B Following 3 Doses of Engerix — 70; 73 Participants
Parkinson's Disease
Primary: Number of Subjects With at Least One Adverse Event During This Open-label Extension Study — 258 Subjects
Infections, Papillomavirus
Primary: Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies — 125; 2; 122; 3 Participants
Infections, Papillomavirus
Primary: Number of Subjects Reporting Serious Adverse Events — 1 Participants
Hypercholesterolemia · Dyslipidemia
Primary: Percent Change From Baseline in Low Density Lipoprotein-cholesterol (LDL-C) at 12 Weeks — -38.99; -34.97; -43.97; -42.84 Percent change
Primary Hypercholesterolemia · Dyslipidemia
Primary: Percent Change From Baseline Low Density Lipoprotein-cholesterol (LDL-C) at Week 12 — -37.89; -38.76; -45.5; -43.9 percent change
Infections, Papillomavirus
Primary: Number of Subjects With Persistent Cervical Infection With Human Papillomavirus 16 (HPV-16) or Human Papillomavirus 18 (HPV-18) — 0; 15; 0; 11 Participants
Infections, Papillomavirus
Primary: Number of Subjects With Anti-human Papilloma Virus-16 (Anti-HPV-16) and Anti-HPV-18 Antibody Titers Greater Than or Equal to Pre-defined Cut-off Values — 61; 30; 57; 45…
Dry Eye Syndrome
Primary: Change From Baseline at Day 30 in Ocular Surface Disease Index© Questionnaire Score — 44; 45.2; -12.6; -13.6 Units on a scale
Peanut Hypersensitivity
Primary: Serious Adverse Events — 0; 1; 0; 1 participants
Hypertension
Primary: Change From Baseline in Trough Seated Diastolic Blood Pressure (DBP) — -5.71; -7.95; -9.35; -10.63 mmHg — p=<0.0001
Infections, Papillomavirus
Primary: Number of Subjects Who Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies — 112; 4; 106; 2…
Infections, Papillomavirus
Primary: Number of Subjects Who Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies — 124; 16; 117; 4…
Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline to Day 42 Endpoint in Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator Administered and Scored…
Asthma
Primary: Percentage of Symptom-free Days During the Last 10 Weeks of the Treatment Period — 50.45; 49.75 percentage of days — p=0.63